24 December 2024 Datopotamab deruxtecan application in the EU for patients with advancednonsquamous non-small cell lung cancer voluntarily withdrawn AstraZeneca and Daiichi Sankyo have voluntarily withdrawn the marketing authorisation application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small …
